Q32 Bio Inc (QTTB) - Net Assets
Based on the latest financial reports, Q32 Bio Inc (QTTB) has net assets worth $46.31 Million USD as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($63.67 Million) and total liabilities ($17.36 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check tangible net worth ratio of Q32 Bio Inc to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $46.31 Million |
| % of Total Assets | 72.73% |
| Annual Growth Rate | 21.1% |
| 5-Year Change | -75.24% |
| 10-Year Change | N/A |
| Growth Volatility | 458.65 |
Q32 Bio Inc - Net Assets Trend (2016–2025)
This chart illustrates how Q32 Bio Inc's net assets have evolved over time, based on quarterly financial data. See Q32 Bio Inc (QTTB) liquidity interval to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Q32 Bio Inc (2016–2025)
The table below shows the annual net assets of Q32 Bio Inc from 2016 to 2025. For live valuation and market cap data, see market value of Q32 Bio Inc.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $42.01 Million | +640.33% |
| 2024-12-31 | $5.67 Million | +103.10% |
| 2023-12-31 | $-182.92 Million | -39.94% |
| 2022-12-31 | $-130.71 Million | -177.05% |
| 2021-12-31 | $169.65 Million | -13.44% |
| 2020-12-31 | $196.00 Million | -24.18% |
| 2019-12-31 | $258.51 Million | +31.65% |
| 2018-12-31 | $196.35 Million | +99.73% |
| 2017-12-31 | $98.31 Million | +1210.72% |
| 2016-12-31 | $7.50 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Q32 Bio Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 19480299700.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $2.00K | 0.00% |
| Other Components | $247.00 Million | 587.91% |
| Total Equity | $42.01 Million | 100.00% |
Q32 Bio Inc Competitors by Market Cap
The table below lists competitors of Q32 Bio Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
The Platform Group AG
XETRA:TPG
|
$91.08 Million |
|
Aifeex Nexus Acquisition Corporation
NASDAQ:AIFE
|
$91.13 Million |
|
Mevaco S.A
AT:MEVA
|
$91.14 Million |
|
Centro de Imagem Diagnósticos S.A
SA:AALR3
|
$91.16 Million |
|
Awea Mechantronic Co Ltd
TW:1530
|
$91.05 Million |
|
Sree Rayalaseema Hi-Strength Hypo Limited
NSE:SRHHYPOLTD
|
$91.04 Million |
|
Hyosung Itx
KO:094280
|
$91.04 Million |
|
Y-Optics Manufacture Co. Ltd
KQ:066430
|
$90.99 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Q32 Bio Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 5,675,000 to 42,014,000, a change of 36,339,000 (640.3%).
- Net income of 29,821,000 contributed positively to equity growth.
- Other factors increased equity by 6,518,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $29.82 Million | +70.98% |
| Other Changes | $6.52 Million | +15.51% |
| Total Change | $- | 640.33% |
Book Value vs Market Value Analysis
This analysis compares Q32 Bio Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.49x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 3.30x to 3.49x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | $3.61 | $11.90 | x |
| 2017-12-31 | $47.28 | $11.90 | x |
| 2018-12-31 | $123.79 | $11.90 | x |
| 2019-12-31 | $110.48 | $11.90 | x |
| 2020-12-31 | $76.84 | $11.90 | x |
| 2021-12-31 | $55.24 | $11.90 | x |
| 2022-12-31 | $55.81 | $11.90 | x |
| 2023-12-31 | $-56.83 | $11.90 | x |
| 2024-12-31 | $0.47 | $11.90 | x |
| 2025-12-31 | $3.41 | $11.90 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Q32 Bio Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 70.98%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 55.49%
- • Asset Turnover: 0.87x
- • Equity Multiplier: 1.47x
- Recent ROE (70.98%) is above the historical average (-112.26%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | -107.29% | 0.00% | 0.00x | 1.90x | $-8.80 Million |
| 2017 | -30.51% | 0.00% | 0.00x | 1.40x | $-39.82 Million |
| 2018 | -28.30% | -1044.29% | 0.02x | 1.32x | $-75.21 Million |
| 2019 | -40.20% | -6237.45% | 0.01x | 1.20x | $-129.77 Million |
| 2020 | -65.66% | -4762.92% | 0.01x | 1.35x | $-148.29 Million |
| 2021 | -56.45% | -281.90% | 0.16x | 1.25x | $-112.73 Million |
| 2022 | -24.05% | -643.65% | 0.11x | 0.35x | $-60.61 Million |
| 2023 | 0.00% | 0.00% | -0.14x | 0.00x | $-35.45 Million |
| 2024 | -841.11% | 0.00% | 0.00x | 16.27x | $-48.30 Million |
| 2025 | 70.98% | 55.49% | 0.87x | 1.47x | $25.62 Million |
Industry Comparison
This section compares Q32 Bio Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $27,896,581
- Average return on equity (ROE) among peers: -64.77%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Q32 Bio Inc (QTTB) | $46.31 Million | -107.29% | 0.37x | $91.06 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $85.57 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $1.61 Billion |
| Abeona Therapeutics Inc (ABEO) | $4.06 Million | -282.32% | 0.21x | $328.21 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $70.43 Million | -172.28% | 0.74x | $155.29 Million |
| Abpro Holdings, Inc. (ABP) | $-75.73 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $189.45 Million | -60.80% | 0.14x | $1.01 Billion |
| Arbutus Biopharma Corp (ABUS) | $35.44 Million | -26.32% | 0.18x | $831.63 Million |
| ABVC Biopharma Inc (ABVC) | $-1.46 Million | 0.00% | 0.00x | $35.10 Million |
| Abivax SA American Depositary Shares (ABVX) | $34.02 Million | -17.32% | 0.13x | $7.90 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $67.16 Million | -67.08% | 0.33x | $3.66 Billion |
About Q32 Bio Inc
Q32 Bio Inc., a clinical-stage biotechnology company, develops novel biologics to restore healthy immune balance in patients with alopecia areata and other autoimmune and inflammatory diseases driven by pathological immune dysfunction. The company is developing Bempikibart (ADX-914), a fully human anti"interleukin-7 receptor alpha antagonist monoclonal antibody which completed Phase 2a clinical t… Read more